Phase 3, single-center, sequential and parallel-group, double-blind, randomized study evaluating the efficacy and safety of Fexofenadine Hydrochloride 180 mg (Allegra®/Telfast®) versus placebo in subjects suffering from seasonal Allergic Rhinitis with symptoms aggravated in presence of pollutants

Authors
Category Primary study
JournalWorld Allergy Organization Journal
Year 2020
This article has no abstract
Epistemonikos ID: e3e90a2eac36d255f354c99fa7f67c50340acee5
First added on: Feb 12, 2025